Regencell Bioscience Holdings (RGC) Accumulated Expenses (2020 - 2025)

Regencell Bioscience Holdings has reported Accumulated Expenses for 6 years, with the latest figure at $1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $348354.0, up 177.95% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $1.4 million, up from $348354.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.4 million in Q4 2025, with the low at $125328.0 in Q2 2024.
• Historically, Accumulated Expenses has averaged $460579.2 across 5 years, with a median of $253217.5 in 2023.
• Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 503.15% — and 2022, when it tumbled 73.62%.
• Regencell Bioscience Holdings' Accumulated Expenses stood at $572990.0 in 2021, then plunged by 73.62% to $151127.0 in 2022, then gained by 4.6% to $158081.0 in 2023, then slipped by 20.72% to $125328.0 in 2024, then jumped by 1023.13% to $1.4 million in 2025.
• The last three Accumulated Expenses figures came in at $1.4 million (Q4 2025), $348354.0 (Q2 2025), and $125328.0 (Q2 2024), per Business Quant data.